摘要
背景:尽管在医学治疗方面取得了进展,但在炎症性肠病(IBD)的治疗中,手术在治疗疾病并发症以及药物治疗失败的情况中一直保持主导地位。 目标:讨论克罗恩病和溃疡性结肠炎外科治疗辩论领域个性化的可能作用。 结论:手术越来越微创,在单一病人的需求量身定制的指南和个性化治疗之间挣扎求存。 IBD手术没有固定管理的空间。 量身定制的方法是每个特定患者获得更好结果的关键。
关键词: 克罗恩氏病,炎性肠病,手术,个性化,量身定制的手术,溃疡性结肠炎。
图形摘要
Current Drug Targets
Title:Can Surgery for Inflammatory Bowel Disease be Personalized?
Volume: 19 Issue: 7
关键词: 克罗恩氏病,炎性肠病,手术,个性化,量身定制的手术,溃疡性结肠炎。
摘要: Background: In the treatment of Inflammatory Bowel Diseases (IBD) despite advances in medical therapies, surgery has maintained a leading role in the management of complications of the disease, as well as in cases of failure of medical therapy.
Objective: discuss the possible role for a personalization in debated fields of surgical treatment of Crohn's disease and ulcerative colitis.
Conclusions: Surgery has become more and more minimally invasive, struggling for a difficult balance between guidelines and personalized treatment tailored on the single patient's need. There is no room for fixed management for surgery in IBD. A tailored approach is key to better outcome in each specific patient.
Export Options
About this article
Cite this article as:
Can Surgery for Inflammatory Bowel Disease be Personalized?, Current Drug Targets 2018; 19 (7) . https://dx.doi.org/10.2174/1389450118666170105153646
DOI https://dx.doi.org/10.2174/1389450118666170105153646 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Bacteria to Antineoplastic: Epothilones A Successful History
Anti-Cancer Agents in Medicinal Chemistry Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Subject index to volume 3
Current Cancer Drug Targets Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Current Status and Future of Target-Based Therapeutics
Current Cancer Drug Targets Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs
Anti-Cancer Agents in Medicinal Chemistry Aptamer-Based Carbohydrate Recognition
Current Pharmaceutical Design Evaluation of Drug Transporter Interactions in Drug Discovery and Development
Combinatorial Chemistry & High Throughput Screening Possible Role of DNA Methylation in the Induction of Systemic Lupus Erythematosus
Current Rheumatology Reviews The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Heterologous Expression and Characterization of Flavinadenine Dinucleotide Synthetase from <i>Candida famata</i> for Flavin Adenine Dinucleotide Production
Protein & Peptide Letters Bcl-2 Family Proteins Regulate Apoptosis and Epithelial to Mesenchymal Transition by Calcium Signals
Current Pharmaceutical Design Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Identification of the Altered Proteins Related to Colon Carcinogenesis by iTRAQ-based Quantitative Proteomic Analysis
Current Proteomics Editorial: Role of Cancer Stem Cells in Common Gastrointestinal Cancers: From Pathogenesis to Therapeutic Targets
Current Stem Cell Research & Therapy Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway
Current Cancer Drug Targets